Status:
COMPLETED
Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females
Lead Sponsor:
University of Campinas, Brazil
Collaborating Sponsors:
Germed Pharma
Conditions:
Overweight
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
Orlistat is a popular drug approved for long-term use which produces weight loss by inhibiting triglycerides, main components of fats in the diet and reducing dietary fat absorption by up to 30%. The ...
Detailed Description
Obesity treatment requires lifestyle changes such as diet, exercise, and behavioral therapy. Orlistat is a popular drug approved for long-term use which produces weight loss by inhibiting triglyceride...
Eligibility Criteria
Inclusion
- Obesity BMC (Body Mass Index) between 30 to 40 kg/m2 Women 18 to 45 years Premenopausal stage
Exclusion
- Relevant diseases (diabetes, cardiovascular, gastrointestinal, renal and hepatic diseases, endocrine disorders, hemoglobinopatHy or neoplasm in the last three years)
- Chemical or natural laxatives
- Weight variation greater than 5% in the preceding 3 months
- Surgery for weight reduction
- Drugs to obesity control and/or oral corticosteroids anti-inflammatory in the last three months
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT01414465
Start Date
October 1 2009
End Date
June 1 2011
Last Update
August 11 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LIMED (Laboratory of Investigation of Metabolism and Diabetes)/GASTROCENTRO/University of Campinas (UNICAMP)
Campinas, São Paulo, Brazil, 13083-878